<DOC>
	<DOCNO>NCT01656343</DOCNO>
	<brief_summary>- To estimate incidence rate post-transplant lymphoproliferative disorder ( PTLD ) adult , EBV seropositive , kidney alone transplant recipient treat belatacept time transplantation - To estimate incidence rate PTLD adult , EBV seropositive , kidney alone transplant recipient treat calcineurin inhibitor ( CNI ) -based regimens time transplantation - To compare PTLD incidence rate adult , EBV seropositive , kidney alone transplant recipient treat belatacept rate adult , EBV seropositive , kidney alone transplant recipient treat CNI-based regimen time transplantation</brief_summary>
	<brief_title>Belatacept Risk Post-transplant Lymphoproliferative Disorder US Renal Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Adult , EBV seropositive , Kidney transplant recipient initiate belatacept adult , EBV seropositive , kidney transplant recipient initiate CNIs report United Network Organ Sharing ( UNOS ) period recruit belatacept user</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>